MFA
BPMC

Mayflower Financial Advisors’s Blueprint Medicines BPMC Stock Holding History

Mayflower Financial Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,817
Closed -$431K – 343
2023
Q2 		$431K Sell
6,817
-12
-0.2% -$652 0.06% 227
2023
Q1 		$307K Buy
6,829
+25
+0.4% +$1.13K 0.04% 262
2022
Q4 		$298K Sell
6,804
-9
-0.1% -$432 0.04% 263
2022
Q3 		$449K Buy
6,813
+7
+0.1% +$450 0.07% 201
2022
Q2 		$344K Sell
6,806
-393
-5% -$23K 0.05% 233
2022
Q1 		$460K Hold
7,199
– – 0.06% 211
2021
Q4 		$771K Hold
7,199
– – 0.1% 140
2021
Q3 		$738K Buy
+7,199
New +$670K 0.1% 142

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Mayflower Financial Advisors's BPMC Position: Q3 2023 in Review

Mayflower Financial Advisors sold out of Blueprint Medicines (BPMC) in Q3 2023, closing a stake of 6,817 shares — an estimated $431K sold.

Mayflower Financial Advisors first reported a position in BPMC in Q3 2021 and held it in 8 quarters. The position peaked at $771K in Q4 2021. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2023.

  • Mayflower Financial Advisors reported no remaining Blueprint Medicines position as of Q3 2023 after selling out during the quarter.
  • Mayflower Financial Advisors sold 6,817 Blueprint Medicines shares in Q3 2023, an estimated $431K.
  • Mayflower Financial Advisors first reported a position in Blueprint Medicines in Q3 2021 and held it in 8 quarters.
  • Mayflower Financial Advisors's Blueprint Medicines position peaked at $771K in Q4 2021.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2023.

Based on Mayflower Financial Advisors's 13F filing for Q3 2023, filed 12 Oct 2023.